Juan E Camacho Londoño1, Qinghai Tian2, Karin Hammer2, Laura Schröder2, Julia Camacho Londoño3, Jan C Reil4, Tao He5, Martin Oberhofer2, Stefanie Mannebach3, Ilka Mathar6, Stephan E Philipp3, Wiebke Tabellion2, Frank Schweda7, Alexander Dietrich8, Lars Kaestner2, Ulrich Laufs4, Lutz Birnbaumer9, Veit Flockerzi3, Marc Freichel10, Peter Lipp11. 1. Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120 Heidelberg, Germany Experimentelle und Klinische Pharmakologie und Toxikologie, 66421 Homburg, Germany DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Germany. 2. Institut für Molekulare Zellbiologie, 66421 Homburg, Germany. 3. Experimentelle und Klinische Pharmakologie und Toxikologie, 66421 Homburg, Germany. 4. Innere Medizin III Universität des Saarlandes, 66421 Homburg, Germany. 5. DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Germany Research Unit Cardiac Epigenetics, Department of Cardiology, Ruprecht-Karls-Universität Heidelberg, 69120 Heidelberg, Germany Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China. 6. Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120 Heidelberg, Germany Experimentelle und Klinische Pharmakologie und Toxikologie, 66421 Homburg, Germany. 7. Institut für Physiologie, Universität Regensburg, 93053 Regensburg, Germany. 8. Walther-Straub-Institut für Pharmakologie und Toxikologie, LMU, 80336 München, Germany. 9. Transmembrane Signaling Group, NIEHS, PO Box 12233, NC 27709, USA. 10. Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120 Heidelberg, Germany Experimentelle und Klinische Pharmakologie und Toxikologie, 66421 Homburg, Germany DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Germany marc.freichel@pharma.uni-heidelberg.de peter.lipp@uniklinikum-saarland.de. 11. Institut für Molekulare Zellbiologie, 66421 Homburg, Germany marc.freichel@pharma.uni-heidelberg.de peter.lipp@uniklinikum-saarland.de.
Abstract
AIMS: Pathological cardiac hypertrophy is a major predictor for the development of cardiac diseases. It is associated with chronic neurohumoral stimulation and with altered cardiac Ca(2+) signalling in cardiomyocytes. TRPC proteins form agonist-induced cation channels, but their functional role for Ca(2+) homeostasis in cardiomyocytes during fast cytosolic Ca(2+) cycling and neurohumoral stimulation leading to hypertrophy is unknown. METHODS AND RESULTS: In a systematic analysis of multiple knockout mice using fluorescence imaging of electrically paced adult ventricular cardiomyocytes and Mn(2+)-quench microfluorimetry, we identified a background Ca(2+) entry (BGCE) pathway that critically depends on TRPC1/C4 proteins but not others such as TRPC3/C6. Reduction of BGCE in TRPC1/C4-deficient cardiomyocytes lowers diastolic and systolic Ca(2+) concentrations both, under basal conditions and under neurohumoral stimulation without affecting cardiac contractility measured in isolated hearts and in vivo. Neurohumoral-induced cardiac hypertrophy as well as the expression of foetal genes (ANP, BNP) and genes regulated by Ca(2+)-dependent signalling (RCAN1-4, myomaxin) was reduced in TRPC1/C4 knockout (DKO), but not in TRPC1- or TRPC4-single knockout mice. Pressure overload-induced hypertrophy and interstitial fibrosis were both ameliorated in TRPC1/C4-DKO mice, whereas they did not show alterations in other cardiovascular parameters contributing to systemic neurohumoral-induced hypertrophy such as renin secretion and blood pressure. CONCLUSIONS: The constitutively active TRPC1/C4-dependent BGCE fine-tunes Ca(2+) cycling in beating adult cardiomyocytes. TRPC1/C4-gene inactivation protects against development of maladaptive cardiac remodelling without altering cardiac or extracardiac functions contributing to this pathogenesis. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Pathological cardiac hypertrophy is a major predictor for the development of cardiac diseases. It is associated with chronic neurohumoral stimulation and with altered cardiac Ca(2+) signalling in cardiomyocytes. TRPC proteins form agonist-induced cation channels, but their functional role for Ca(2+) homeostasis in cardiomyocytes during fast cytosolic Ca(2+) cycling and neurohumoral stimulation leading to hypertrophy is unknown. METHODS AND RESULTS: In a systematic analysis of multiple knockout mice using fluorescence imaging of electrically paced adult ventricular cardiomyocytes and Mn(2+)-quench microfluorimetry, we identified a background Ca(2+) entry (BGCE) pathway that critically depends on TRPC1/C4 proteins but not others such as TRPC3/C6. Reduction of BGCE in TRPC1/C4-deficient cardiomyocytes lowers diastolic and systolic Ca(2+) concentrations both, under basal conditions and under neurohumoral stimulation without affecting cardiac contractility measured in isolated hearts and in vivo. Neurohumoral-induced cardiac hypertrophy as well as the expression of foetal genes (ANP, BNP) and genes regulated by Ca(2+)-dependent signalling (RCAN1-4, myomaxin) was reduced in TRPC1/C4 knockout (DKO), but not in TRPC1- or TRPC4-single knockout mice. Pressure overload-induced hypertrophy and interstitial fibrosis were both ameliorated in TRPC1/C4-DKO mice, whereas they did not show alterations in other cardiovascular parameters contributing to systemic neurohumoral-induced hypertrophy such as renin secretion and blood pressure. CONCLUSIONS: The constitutively active TRPC1/C4-dependent BGCE fine-tunes Ca(2+) cycling in beating adult cardiomyocytes. TRPC1/C4-gene inactivation protects against development of maladaptive cardiac remodelling without altering cardiac or extracardiac functions contributing to this pathogenesis. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Scott A Henderson; Joshua I Goldhaber; Jessica M So; Tieyan Han; Christi Motter; An Ngo; Chana Chantawansri; Matthew R Ritter; Martin Friedlander; Debora A Nicoll; Joy S Frank; Maria C Jordan; Kenneth P Roos; Robert S Ross; Kenneth D Philipson Journal: Circ Res Date: 2004-08-12 Impact factor: 17.367
Authors: Hsuan-Ting Huang; Ondra M Brand; Matthen Mathew; Christos Ignatiou; Elizabeth P Ewen; Sarah A McCalmon; Francisco J Naya Journal: J Biol Chem Date: 2006-10-17 Impact factor: 5.157
Authors: Alexander Dietrich; Michael Mederos Y Schnitzler; Maik Gollasch; Volkmar Gross; Ursula Storch; Galyna Dubrovska; Michael Obst; Eda Yildirim; Birgit Salanova; Hermann Kalwa; Kirill Essin; Olaf Pinkenburg; Friedrich C Luft; Thomas Gudermann; Lutz Birnbaumer Journal: Mol Cell Biol Date: 2005-08 Impact factor: 4.272
Authors: Erik W Bush; David B Hood; Philip J Papst; Joseph A Chapo; Wayne Minobe; Michael R Bristow; Eric N Olson; Timothy A McKinsey Journal: J Biol Chem Date: 2006-09-01 Impact factor: 5.157
Authors: Koichiro Kuwahara; Yanggan Wang; John McAnally; James A Richardson; Rhonda Bassel-Duby; Joseph A Hill; Eric N Olson Journal: J Clin Invest Date: 2006-11-09 Impact factor: 14.808
Authors: Yue-Kun Ju; Yi Chu; Herve Chaulet; Donna Lai; Othon L Gervasio; Robert M Graham; Mark B Cannell; David G Allen Journal: Circ Res Date: 2007-05-03 Impact factor: 17.367
Authors: Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Elisabeth Kaiser; Qinghai Tian; Michael Wagner; Monika Barth; Wenying Xian; Laura Schröder; Sandra Ruppenthal; Lars Kaestner; Ulrich Boehm; Philipp Wartenberg; Huiyan Lu; Sara M McMillin; Derek B J Bone; Jürgen Wess; Peter Lipp Journal: Cardiovasc Res Date: 2019-05-01 Impact factor: 10.787
Authors: Kevin J Morine; Vikram Paruchuri; Xiaoying Qiao; Mark Aronovitz; Gordon S Huggins; David DeNofrio; Michael S Kiernan; Richard H Karas; Navin K Kapur Journal: Cardiovasc Pathol Date: 2016-08-21 Impact factor: 2.185